Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3540378 in adults with worsening chronic heart failure with preserved ejection fraction (HFpEF)
2022-000780-48Phase 2Active
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2022
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in heart failure with preserved ejection fraction (HFpEF) and chronic heart failure (CHF) comparing LY3540378 SC QW with Placebo SC QW (2 arms). Primary endpoint: Primary: Change from baseline to Week 26 in LARS. Started Sep 2022; status: active.
02
Drugs
volenrelaxin
03
Conditions
heart failure with preserved ejection fraction (HFpEF)chronic heart failure (CHF)
Beyond the preview
Go deeper on 2022-000780-48.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000780-48.